Article
Exploring New Treatment Options In HCC
Author(s):
This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.
Date/Time: Tuesday, June 23, 2020 at 8 PM EST
This OncLive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC.
The following topics will be discussed:
- Impact of the COVID pandemic on reentry and reopening
- Selection of therapy during the pandemic, oral versus IV therapies and immunotherapy
- Recent approval of atezolizumab + bevacizumab and how this will impact the treatment landscape of HCC
Associate Professor of Clinical Medicine; Medical Director of Clinical Investigations Support Office; Phase I program director, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Amit G. Singal, MD, David Bruton Jr. Professor in Clinical Cancer Research; Associate Professor of Medicine; Medical Director of Liver Tumor Program; Clinical Chief of Hepatology, University of Texas Southwestern, Dallas, TX
Catherine T. Frenette, MD, Director of Gastroenterology, Transplant Hepatology, MD Anderson Cancer Center, La Jolla,CA
Sponsored By:
